248 related articles for article (PubMed ID: 19638627)
21. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
22. c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance.
Li F; Xiong Y; Yang M; Chen P; Zhang J; Wang Q; Xu M; Wang Y; He Z; Zhao X; Huang J; Gu X; Zhang L; Sun R; Sun X; Li J; Ou J; Xu T; Huang X; Cao Y; Xu XR; Karakas D; Li J; Ni H; Zhang Q
Cell Death Dis; 2022 Oct; 13(10):869. PubMed ID: 36229456
[TBL] [Abstract][Full Text] [Related]
23. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy.
Roussy M; Bilodeau M; Jouan L; Tibout P; Laramée L; Lemyre E; Léveillé F; Tihy F; Cardin S; Sauvageau C; Couture F; Louis I; Choblet A; Patey N; Gendron P; Duval M; Teira P; Hébert J; Wilhelm BT; Choi JK; Gruber TA; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2018 Jun; 57(6):311-319. PubMed ID: 29427526
[TBL] [Abstract][Full Text] [Related]
24. Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.
Morita K; Noura M; Tokushige C; Maeda S; Kiyose H; Kashiwazaki G; Taniguchi J; Bando T; Yoshida K; Ozaki T; Matsuo H; Ogawa S; Liu PP; Nakahata T; Sugiyama H; Adachi S; Kamikubo Y
Sci Rep; 2017 Nov; 7(1):16604. PubMed ID: 29192243
[TBL] [Abstract][Full Text] [Related]
25. Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.
Jakobczyk H; Debaize L; Soubise B; Avner S; Rouger-Gaudichon J; Commet S; Jiang Y; Sérandour AA; Rio AG; Carroll JS; Wichmann C; Lie-A-Ling M; Lacaud G; Corcos L; Salbert G; Galibert MD; Gandemer V; Troadec MB
J Hematol Oncol; 2021 Mar; 14(1):47. PubMed ID: 33743795
[TBL] [Abstract][Full Text] [Related]
26. Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.
Tabellini G; Tazzari PL; Bortul R; Billi AM; Conte R; Manzoli L; Cocco L; Martelli AM
Br J Haematol; 2004 Aug; 126(4):574-82. PubMed ID: 15287952
[TBL] [Abstract][Full Text] [Related]
27. Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.
Lo KC; Chalker J; Strehl S; Neat M; Smith O; Dastugue N; Kearney L; Izraeli S; Kempski H; Cowell JK
Br J Haematol; 2008 Sep; 142(6):934-45. PubMed ID: 18557744
[TBL] [Abstract][Full Text] [Related]
28. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
29. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes.
Jenkins CE; Gusscott S; Wong RJ; Shevchuk OO; Rana G; Giambra V; Tyshchenko K; Islam R; Hirst M; Weng AP
Exp Hematol; 2018 Aug; 64():84-96. PubMed ID: 29733873
[TBL] [Abstract][Full Text] [Related]
30. [Blocking PAK1 kinase activity promotes the differentiation of acute megakaryocytic leukemia cells and induces their apoptosis].
Wang SJ; Wang CQ; Hu XT; Yu XR; Fu CL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):499-505. PubMed ID: 35968594
[No Abstract] [Full Text] [Related]
31. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
32. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
33. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
[TBL] [Abstract][Full Text] [Related]
34. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.
Mercher T; Raffel GD; Moore SA; Cornejo MG; Baudry-Bluteau D; Cagnard N; Jesneck JL; Pikman Y; Cullen D; Williams IR; Akashi K; Shigematsu H; Bourquin JP; Giovannini M; Vainchenker W; Levine RL; Lee BH; Bernard OA; Gilliland DG
J Clin Invest; 2009 Apr; 119(4):852-64. PubMed ID: 19287095
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
36. RUNX1 Upregulation Causes Mitochondrial Dysfunction via Regulating the PI3K-Akt Pathway in iPSC from Patients with Down Syndrome.
Liu Y; Zhang Y; Ren Z; Zeng F; Yan J
Mol Cells; 2023 Apr; 46(4):219-230. PubMed ID: 36625318
[TBL] [Abstract][Full Text] [Related]
37. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
38. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
39. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
[TBL] [Abstract][Full Text] [Related]
40. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome.
Lightfoot J; Hitzler JK; Zipursky A; Albert M; Macgregor PF
Leukemia; 2004 Oct; 18(10):1617-23. PubMed ID: 15343346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
